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Abstract 
JAK kinases classically signal by activating STAT transcription factors, but can also regulate gene 
expression by epigenetically phosphorylating histone H3 on tyrosine 41 (H3Y41-P).  In diffuse large B 
cell lymphomas (DLBCL), JAK signaling is a feature of the ABC subtype and is triggered by autocrine 
production of IL-6 and IL-10.  Whether this signaling involves STAT activation, epigenetic 
modification of chromatin or both mechanisms is unknown.  Here we use genetic and pharmacological 
inhibition to show that JAK1 signaling sustains the survival of ABC DLBCL cells.  While STAT3 
contributed to the survival of ABC DLBCL cell lines, forced STAT3 activity could not protect these 
cells from death following JAK1 inhibition, suggesting epigenetic JAK1 action.  JAK1 regulated the 
expression of nearly 3,000 genes in ABC DLBCL cells, and the chromatin surrounding many of these 
genes was modified by H3Y41-P marks that were diminished by JAK1 inhibition.  These JAK1 
epigenetic target genes encode important regulators of ABC DLBCL proliferation and survival, 
including IRF4, MYD88 and MYC.  A small molecule JAK1 inhibitor cooperated with the BTK 
inhibitor ibrutinib in reducing IRF4 levels and acted synergistically to kill ABC DLBCL cells, 
suggesting that this combination should be evaluated in clinical trials. 
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Significance  
Autocrine cytokine signaling in cancer can activate members of the JAK kinase family, which are 
generally thought to act by phosphorylating STAT family transcription factors.  We report here that 
JAK1 mediates autocrine IL-6 and IL-10 cytokine signaling in ABC DLBCL by a non-canonical 
epigenetic regulatory mechanism involving phosphorylation of histone H3 on tyrosine 41.  By 
genome-wide assessment, we have identified target genes that are activated in ABC DLBCL by this 
epigenetic mechanism.  Knowledge of these epigenetic targets led to our demonstration that small 
molecule JAK1 inhibitors synergize with inhibitors of chronic active B cell receptor signaling in ABC 
DLBCL, suggesting a new therapeutic strategy for this subtype of DLBCL, which is the most difficult 
to cure with current therapy.  
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Introduction 
 Diffuse large B cell lymphoma (DLBCL), a B cell non-Hodgkin lymphoma, represents 30% to 
40% of newly diagnosed lymphomas, and includes two main molecular subtypes termed activated B 
cell-like (ABC) and germinal center B cell-like (GCB) (1, 2). ABC DLBCL is more aggressive, with a 
current cure rate of only ~40% (3). One distinct feature of this lymphoma is autocrine signaling 
mediated by the cytokines IL-6 and IL-10, which constitutively activates the transcription factor 
STAT3 (4-6). Autocrine production of these cytokines results from high NF-κB activity (7), which is a 
hallmark of ABC DLBCL (4, 8-10). The NF-κB pathway can be engaged by a variety of genetic 
alterations in ABC DLBCL (9, 11, 12), including somatic mutations targeting components of the B cell 
receptor (BCR) and Toll-like receptor (TLR) signaling pathways.  For example, 39% of ABC DLBCL 
tumors have mutations in the gene encoding MYD88, a key signaling adaptor in Toll-like receptor 
signaling (9).  The most prevalent MYD88 mutation (L265P), which is present in 29% of ABC 
DLBCL tumors, promotes cell survival by engaging the NF-κB pathway and inducing production of 
IL-6 and/or IL-10.  NF-κB is also activated in ABC DLBCL by gain-of-function mutations in the B 
cell receptor (BCR) pathway, including mutations targeting the BCR components CD79A and CD79B 
(11) and the downstream signaling adaptor CARD11 (13). Targeting BCR signaling with ibrutinib, a 
specific inhibitor for Bruton tyrosine kinase (BTK), has emerged as a promising therapy for ABC 
DLBCL (14).   
IL-6 and IL-10 function through their respective receptors and activate members of the Janus 
kinase (JAK) family (15, 16).  In mammals, the JAK family has 4 members: JAK1, JAK2, JAK3, and 
TYK2 (15).  JAKs phosphorylate STAT family members to promote STAT dimerization, nuclear 
translocation, and binding to cis-regulatory elements to regulate transcription (15, 17).  This canonical 
JAK/STAT pathway is deregulated in several hematologic malignancies (16). In DLBCL, STAT3 is 
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activated in the ABC subtype and regulates gene expression to promote the survival of the malignant 
cells (6, 18). 
A separate, non-canonical mechanism by which JAK activity perturbs gene expression is by 
directly phosphorylating chromatin, which was first discovered in Drosophila (19) and subsequently 
confirmed in human cells (20-22).  In leukemia cells, a mutant JAK2 isoform phosphorylates the tail of 
histone H3 tyrosine 41 (H3Y41), which displaces the inhibitory heterochromatin protein HP1α from 
chromatin to augment gene transcription (20, 23).  We previously reported a similar function of JAK2 
in primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL), in which JAK2 
kinase is activated by autocrine IL-13 signaling (21, 24).  Through this non-canonical pathway, JAK2 
induces expression of more than 2,000 genes, including genes that control the growth and proliferation 
of the malignant cell such as MYC, JMJD2C, and JAK2 itself, as well as the genes encoding PD-L1 
and PD-L2, which inhibit tumor immunity through the T cell inhibitory receptor PD1 (21, 24, 25).  
Here, we demonstrate that JAK1 promotes the malignant phenotype of ABC DLBCL cells by 
phosphorylating and activating STAT3 and also epigentically by phosphorylating chromatin on 
H3Y41.  We demonstrate that some epigenetic JAK1 target genes are also induced by the BCR/NF-κB 
signaling pathway and that co-targeting of BCR and JAK signaling with small molecule inhibitors kills 
ABC DLBCL cells synergistically. 
 
Results 
 JAK1 is required for the survival of ABC DLBCL cells.  
The essential role of autocrine IL-6 or IL-10 signaling in the survival of ABC DLBCL cells has 
been demonstrated (4, 5), but the molecular mechanisms by which these cytokines promote 
lymphomagenesis are largely unknown.  As a first step, we examined the viability of DLBCL cell lines 
treated with AZD1480, an inhibitor of JAK1 and JAK2 (26).  AZD1480 potently decreased cell 
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viability in ABC but not GDC DLBCL lines (Fig. 1A), and induced apoptosis in ABC DLBCL lines, 
as indicated by active caspase 3 and cleaved PARP (Fig. 1B).  Selective toxicity to ABC DLBCL cell 
lines was also observed with another inhibitor of JAK1 and JAK2, ruxolitinib (Fig. 1A) (27).  Since 
JAK2 is not activated in ABC DLBCL cells (21), we tested whether JAK1 is the target of AZD1480 
action in these lymphomas. Due to the difficulty in detecting JAK1 phosphorylation by a direct 
immunoblotting assay, we first immunoprecipitated tyrosine-phosphorylated proteins and then 
immunoblotted with an antibody that detects JAK1 phosphorylation.  By this method, JAK1 
phosphorylation was evident in all ABC DLBCL cell lines tested and was reduced when cells were 
treated with AZD1480 (Fig. 1C). 
To investigate the consequence of JAK1 activity in ABC DLBCL, we developed JAK1-specific 
small hairpin RNAs (shRNAs) that mediate RNA interference and expressed them using a retroviral 
vector that co-expresses green fluorescent protein (GFP).  We identified two shRNAs that reduced 
JAK1 expression by 50% to 70% (Fig. S1A and B).  Following retroviral infection, the percentage of 
viable shRNA-expressing (GFP+) cells relative to day 0 was monitored over time by fluorescence 
activated cell sorting (FACS).   Over the course of 12 days, JAK1 shRNA expression decreased the 
viability of all 6 ABC DLBCL lines examined, whereas two GCB DLBCL lines were insensitive (Fig. 
1D).  By contrast, the viability of ABC DLBCL cells was not affected by a JAK2 shRNA (Fig. S1C), 
which is toxic for JAK2-dependent PMBL and HL cell lines (21).  Together, these data demonstrate that 
JAK1 promotes ABC DLBCL cell survival. 
 
JAK1-mediated H3Y41 phosphorylation and epigenetic gene regulation in ABC DLBCL. 
We and others have demonstrated that ABC DLBCL cell survival is promoted by 
overexpression and activation of STAT3 by autocrine IL-6 and IL-10 signaling (4-6). We therefore 
investigated whether a constitutively activated form of STAT3 (STAT3-C) (28) would prevent the 
apoptotic cell death induced by JAK1 inhibition.  STAT3-C forms a dimer that is driven by oxidation 
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of cysteines rather than by JAK-mediated phosphorylation of tyrosine 705, and can transform 
fibroblasts (28, 29).  We used a retrovirus to express STAT3-C in two ABC DLBCL lines, TMD8 and 
HBL1, and immunoblot analysis demonstrated that STAT3-C increased the levels of active, 
phosphorylated STAT3 (Fig. 2A, left).  To test the ability of STAT3-C to promote ABC DLBCL 
survival, we knocked down endogenous STAT3 expression using an shRNA targeting the STAT3 3’ 
untranslated region in two ABC DLBCL lines that had been transduced with either STAT3-C or an 
empty vector.  In cells transduced with empty vector, STAT3 knockdown caused a time-dependent loss 
of viable cells, but this was reversed by expression of STAT3-C (Fig. 2B).  By contrast, in two ABC 
DLBCL lines induced to express a JAK1 shRNA, expression of STAT3-C produced partial or no 
rescue of viability, whereas ectopic expression of JAK1 itself was able to rescue the cells (Fig. 2C).   
These findings suggested that STAT3 mediates some but not all of the pro-survival function of 
JAK1 in ABC DLBCL cells, prompting us to investigate the role of non-canonical JAK signaling in 
these cells.  First, we investigated the subcellular distribution of JAK1 in ABC DLBCL cell lines.  
JAK1 was detected in cytoplasmic fractions enriched for tubulin but also in nuclear extracts enriched 
for histone H3, consistent with the possibility of non-canonical JAK1 signaling in the nucleus (Fig. 
3A).  Since non-canonical JAK2 signaling in PMBL and HL promotes expression of MYC (21), we 
investigated whether this is also true for JAK1 in ABC DLBCL.  Immunoblot analysis revealed that 
MYC expression was strongly reduced following knockdown of JAK1 in ABC DLBCL cells, but was 
not affected by knockdown of JAK2 (Fig. 3B).  The small molecule JAK1 inhibitors AZD1480 and 
ruxolitinib also significantly reduced MYC expression in a dose-dependent manner (Fig. 3C).  
Moreover, these inhibitors decreased global H3Y41 phosphorylation, consistent with non-canonical 
JAK1 signaling (Fig. 3C).  
We next investigated H3Y41 phosphorylation at the MYC locus by chromatin 
immunoprecipitation (ChIP) and quantitative PCR analysis using primers spanning several regulatory 
regions of the MYC locus, as described (21). We performed this analysis in TMD8 ABC DLBCL cells 
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treated with the JAK1 inhibitor AZD1480 or with DMSO as a control. H3Y41 phosphorylation was 
evident at several MYC regions, and AZD1480 reduced these ChIP signals.  The largest effect was 
observed at a regulatory region in intron 1 (Fig. 3D) that is also phosphorylated by JAK2 in PMBL and 
HL cells (21).  These data suggest that the potent upregulation of MYC by JAK1 is a consequence of 
H3Y41 phosphorylation of the MYC locus.  
 
Identification of JAK1 target genes by H3Y41-P ChIP-seq in ABC DLBCL. 
To identify the targets of non-canonical JAK1 signaling genome-wide, we performed H3Y41-P 
ChIP coupled with next-generation sequencing (ChIP-Seq) in the ABC DLBCL cell line TMD8.  
Using a stringent filter for peak calling, we identified a total of 36,634 H3Y41-P peaks (Dataset S1), 
with the vast majority (70.3%) mapping near a protein-coding gene within a window extending from -
15 kilobases (kb) 5’ of the transcriptional start site (TSS) to the 3’ end of any annotated transcript 
associated with the gene.  Of those peaks, 36.3% were located upstream of the proximal promoter (-15 
kb to -2 kb relative to the TSS), 21.4% were within the proximal promoter region (-2 kb to + 2 kb 
relative to the TSS), and the remaining 42.3% mapped within the gene body (+2 kb to the 3’ end of 
annotated transcripts) (Fig. 4A). Similar results were obtained when peak calling was performed at a 
different stringency, confirming that the observed genomic distribution reflects an intrinsic 
characteristic of H3Y41-P and does not depend on the height of the peaks considered for the analysis. 
Notably, treatment of TMD8 cells with the JAK inhibitor AZD1480 reduced H3Y41-P modification at 
the majority of these genomic locations (Fig. 4C).  Peaks in the upstream, promoter and gene body 
regions were similarly affected by AZD1480 treatment (Fig. 4C, bottom panels), consistent with a 
global impairment of non-canonical JAK1 signaling. Notably, less than 1% of H3Y41-P bound sites 
(269/36,634) have a STAT binding motif. 
We identified a total of 4,366 H3Y41-P peaks (associated with 2,956 genes) that were 
significantly reduced by AZD1480 treatment (P <0.01, see Methods for detail) (Dataset S1). This gene 
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regulation mechanism by JAK1 is distinct from the canonical pathway since there is no statistical 
enrichment of the STAT motif within H3Y41-P peaks and more than 90% (2686/2956) of 
corresponding genes do not bear a STAT motif in their promoter region (Dataset S1). To functionally 
validate the role of H3Y41-P in the expression of these genes, we performed a time course analysis of 
gene expression changes resulting from AZD1480 treatment of TMD8 cells. Notably, genes with 
H3Y41-P peaks were enriched among genes that were downregulated by AZD1480 in TMD8 cells 
(P<0.0003, Fischer’s exact test) but not among genes up-regulated by AZD1480 treatment (Fig. 4D). 
Gene Set Enrichment Analysis (GSEA) confirmed a significant enrichment of H3Y41-P+ genes among 
those whose transcription was blocked following JAK1 inhibition (P=2.92 x10-7, Kolmogorov-
Smirnov test; Fig. 4E). In parallel, we performed GSEA using a database of signatures that reflect 
signaling and regulatory processes in normal and malignant hematopoietic cells (30). As expected, 
genes downregulated by AZD1480 treatment were strongly enriched for JAK/STAT-dependent genes, 
as well as for NF-κB target genes (Fig. 4F). Altogether, these findings suggest that JAK1-dependent 
H3Y41 phosphorylation contributes to the transcriptional output of JAK1 signaling. 
Representative genes with JAK1-dependent H3Y41-P peaks are shown in Figure 4G, including 
some that are known to be central to ABC DLBCL biology, such as MYC, IRF4, SPIB and MYD88.  
Reduced IRF4 and MYD88 protein and mRNA expression after JAK1 inhibition was confirmed by 
immunoblot analysis and quantitative PCR in two ABC DLBCL cell lines (Fig. 4H).  To test whether 
MYC, IRF4 and MYD88 are regulated by conventional, JAK1-induced STAT3 activation, we knocked 
down expression of STAT3 with an shRNA or expressed the constitutively active STAT3-C isoform in 
ABC DLBCL cells and then analyzed expression of MYC, IRF4 or MYD88 by immunoblotting.  
MYC expression was not altered in cells expressing either the STAT3 shRNA or STAT3-C, but was 
downregulated by a JAK1 shRNA or by AZD1480 treatment (Fig. S2A and B).  Similar results were 
obtained for IRF4 and MYD88 (Fig. S2C and D).  Thus, these JAK1 target genes are regulated in a 
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STAT3-independent fashion, consistent with non-canonical epigenetic regulation by JAK1.  Other 
genes of note with H3Y41-P peaks that were downregulated by JAK1 inhibition (Fig. 4G) encode the 
transcription factors JUN and JUND, which may contribute to ABC DLBCL survival (31); EGR1, an 
early growth response gene that is induced by BCR stimulation and promotes B cell proliferation and 
differentiation (32, 33); SPHK2, which is a molecular target in primary effusion lymphoma (34); 
ZFP36, an RNA binding protein that regulates mRNA stability (35); and SOCS3, a negative regulator 
of JAK1 signaling (36).  
 
Co-targeting JAK1 and BTK in ABC DLBCL.  
The transcription factor IRF4 is a master regulator of the ABC DLBCL phenotype and is a 
target of both JAK1 signaling (see above) and chronic active BCR signaling in ABC DLBCL (10).  We 
therefore hypothesized that combined inhibition of JAK1 and BCR signaling would have synergistic 
toxicity in ABC DLBCL. To test this, we measured viability of two ABC DLBCL lines, TMD8 and 
OCI-Ly10, and a control GCB DLBCL line OCI-Ly19, following treatment with AZD1480 and/or 
ibrutinib, a BTK inhibitor that blocks BCR-dependent NF-κB activation.  As expected, we observed a 
dose-dependent toxicity of ibrutinib treatment in the TMD8 and OCI-Ly10 lines but not in OCI-Ly19 
(Fig. S3).  Data in Fig. 5A were normalized both to the viability of cells at time 0 and to the viability of 
cells treated with the indicated concentrations of ibrutinib alone.  Addition of ibrutinib to AZD1480 
shifted the viability curves for the two ABC DLBCL lines to the left, indicating more than additive 
killing by the combination, whereas these drugs had no effect on the viability of the GCB DLBCL 
lines (Fig. 5A).   Similarly, when JAK1 was knocked down using an shRNA in ABC DLBCL lines, the 
toxicity was increased by the addition of ibrutinib, but no toxicity of this combination was observed in 
a GCB DLBCL line (Fig. 5B).  
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We next investigated whether decreased IRF4 levels were related to the combined toxicity of 
the JAK1 and BCR signaling inhibitors.  Immunoblot analysis revealed a dose-dependent reduction in 
IRF4 levels with AZD1480 treatment, and the addition of ibrutinib decreased IRF4 levels further (Fig. 
5C).  By contrast, another JAK1 target, MYD88, was decreased in expression by AZD1480, as 
expected, but the addition of ibrutinib did not decrease MYD88 levels further, in keeping with the fact 
that MYD88 levels are not regulated by BCR signaling (Fig. 5C).  Thus, decreased levels of the master 
regulatory transcription factor IRF4 could explain, at least in part, the observed synergistic killing of 
ABC DLBCL cells by JAK1 and BCR signaling inhibitors. 
 
Discussion 
Here we report a novel molecular mechanism by which JAK1 contributes to the malignant 
phenotype of ABC DLBCL.  Although STAT3 is activated in ABC DLBCL cells by JAK1, STAT3 
does not mediate all of the downstream consequences of JAK1 activity since a constitutively active 
STAT3 isoform was unable to sustain ABC DLBCL viability following inhibition of JAK1.  Rather, 
epigenetic regulation by JAK1 plays a prominent role in the gene expression program of ABC DLBCL 
cells by phosphorylating chromatin on H3Y41.  The chromatin of nearly 3,000 genes had JAK1-
dependent H3Y41 phosphorylation marks and required JAK1 for their expression. Two of these direct 
JAK1 epigenetic target genes, IRF4 and MYD88, play pivotal roles in ABC DLBCL biology.  MYD88 
is activated by recurrent somatic mutations in ABC DLBCL, and the ABC DLBCL lines tested harbor 
the MYD88 L265P allele (9).  MYD88 signaling activates the NF-κB and p38 MAP kinase pathways, 
both of which promote the expression of IL-6 and IL-10, which initiate autocrine signaling and activate 
JAK1.  Thus, epigenetic regulation of MYD88 by JAK1 initiates a positive feedback loop.  In addition 
to IL-6 and IL-10, MYD88 induces many other NF-κB target genes, which most likely contribute to 
survival of ABC DLBCL cells (9).  Conversely, MYD88 signaling in ABC DLBCL also activates type 
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I interferon expression, which is toxic for these cells (10).  IRF4 suppresses this type I interferon axis 
by repressing IRF7, a key transcriptional activator of type I interferon genes (10).  Of note, this 
function of IRF4 requires its dimerization with SPIB, which is also an epigenetic target of JAK1 in 
ABC DLBCL cells (10).  An additional important action of IRF4/SPIB is to upregulate CARD11, a 
key signaling adapter that is responsible for NF-κB activation downstream of BCR signaling (10).   
Thus, the epigenetic regulation of IRF4 and SPIB by JAK1 in ABC DLBCL accentuates the pro-
survival NF-κB pathway while dampening the pro-death type I interferon pathway. 
Our study adds to a growing literature demonstrating epigenetic regulation of gene expression 
by JAK kinases, which followed the initial discovery that the Drosophila JAK homolog Hopscotch 
regulates development by preventing heterochromatin formation (19, 37). This non-canonical 
mechanism of JAK signaling was further characterized in human leukemia and lymphoma cells in 
which nuclear JAK2 directly phosphorylates H3Y41, thereby blocking recruitment of the 
heterochromatin protein HP1α (20, 21).  In embryonic stem cells, H3Y41 is phosphorylated by both 
JAK1 and JAK2 and this is essential for self-renewal (22).  In ABC DLBCL, JAK1 epigenetic targets 
are largely non-overlapping with a set of STAT3 target genes defined in ABC DLBCL by integrated 
STAT3 ChIP-Seq with RNA-Seq analysis (18).  Of these STAT3 target genes in ABC DLBCL, most 
(1241/1540, 80.5%) do not have H3Y31-P peaks.  Conversely, of the genes that have H3Y41-P peaks 
in ABC DLBCL and were downregulated by AZD1480 treatment, most (79/113, 70%) were not 
identified as STAT3 target genes.  For example, the JAK1 epigenetic target gene IRF4 does not appear 
to be a target of STAT3 since its expression remains unchanged when STAT3 is knocked down or 
overexpressed (Fig. S2).  STAT3 transactivates the genes encoding IL-6 and IL-10, thereby 
augmenting both the canonical JAK1/STAT3 pathway as well as the non-canonical, JAK1 epigenetic 
pathway.  In addition, STAT3 reinforces the canonical pathway by positively autoregulating its own 
expression (18).  STAT3 also regulates a number of genes that are also regulated by NF-κB, including 
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NFKBIA, NFKBIZ, CXCR5, CD44, and PIM2 (18), which could be due to the ability of STAT3 to 
form complex with NF-κB transcription factors (38).  We conclude that JAK1 uses STAT3-dependent 
and STAT3-independent regulatory mechanisms to influence the malignant phenotype of ABC 
DLBCL cells. 
Our study supports the development of JAK1 inhibitors for the treatment of ABC DLBCL.  We 
demonstrated that JAK1, not JAK2, is required for ABC DLBCL survival, which suggests that JAK1-
selective inhibitors could prove effective in ABC DLBCL.  The JAK inhibitors approved thus far for 
clinical use target multiple JAK family members (see ref. (39) for review).  The drug ruxolitinib, 
approved for treatment of myelofibrosis and polycythemia vera, inhibits both JAK1 and JAK2.  As a 
consequence of JAK2 inhibition, on-target side effects of ruxolitinib include thrombocytopenia and 
anemia.  Tofacitinib is an inhibitor of JAK1, JAK2 and JAK3 that is approved for the treatment of 
rheumatoid arthritis.  JAK3 inhibition blocks T cell responses by preventing signaling by cytokines 
that act through the common gamma chain receptor, including IL-2, IL-7, IL-9, IL-15 and IL-21.  
Selective JAK1 inhibitors are in development that may avoid some side effects associated with 
inhibition of other JAK family members (39) and should be evaluated in ABC DLBCL. 
Although recent clinical investigation of ibrutinib in DLBCL revealed frequent responses in 
ABC DLBCL (14), most responses were not long lasting, suggesting that combinations of targeted 
agents that inhibit distinct survival pathways will be necessary.  Here we provide a rational basis for 
combining JAK1 inhibitors with inhibitors of BCR signaling that block NF-κB activation, such as 
ibrutinib.  We identified IRF4 as a direct target of JAK1 epigenetic regulation, and IRF4 is also a target 
of NF-κB downstream of BCR signaling in ABC DLBCL.  As a consequence, IRF4 levels are reduced 
in ABC DLBCL cells by treatment with ibrutinib (10).  The combination of the JAK1 inhibitor 
AZD1480 and ibrutinib cooperated to reduce IRF4 to undetectable levels, which most likely 
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contributes to their synergy in killing ABC DLBCL cells.  Our findings support the development of 
JAK1 inhibitors in conjunction with ibrutinib for the treatment of ABC DLBCL.  
 
Materials and Methods 
Full details of the methods used and data analysis are presented in SI Text. 
 
Cell lines and culture. All doxycycline-inducible human DLBCL cell lines that express the bacterial 
tetracycline repressor were engineered as described previously (40). Doxycycline (20 ng/ml) was used 
to induce the expression of genes or shRNAs of interest. All cultures were routinely tested for 
mycoplasma contamination. 
 
ChIP-Seq analysis of H3Y41 phosphorylation.  ChIP-enriched DNA samples were used to create 
adapter-ligated libraries for massively parallel sequencing with the ChIP-Seq DNA Sample Prep Kit 
(Illumina) following manufacturer’s protocol, as described previously (21). All ChIP-Seq data are 
available at http://www.ncbi.nlm.nih.gov/geo/ (accession # GSE86264). 
 
Gene expression. Gene expression profiling was performed using Agilent 4X44K whole genome 
arrays, as described previously (21). Signal from DMSO control cells (Cy3) was compared to JAK 
inhibitor-treated cells (Cy5).  Array data are available at http://www.ncbi.nlm.nih.gov/geo/ (accession 
# GSE86265). 
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Figure legends 
 
Fig. 1. JAK1 is required for the survival of ABC DLBCL cells.  (A) MTT viability assay conducted 
in the indicated cell lines after 6 days of treatment with the indicated concentrations of AZD1480 or 
ruxolitinib.  The drugs were replenished every other day. Error bars represent mean ± SD of triplicates. 
(B) Flow cytometric analysis of apoptosis in the indicated cell lines after 3 days treatment of AZD1480 
or DMSO as measured by cells with active caspase 3 and cleaved PARP. (C) Immunoblot analysis of 
JAK phosphorylation in ABC DLBCL cells.  Ten million cells were treated with AZD1480 (2 μM) or 
DMSO for 2 hours before immunoprecipitation with an anti-phospho-tyrosine antibody and subsequent 
immunoblotting using an anti-phospho-JAK1 antibody. NS denotes non-specific bands. (D) Flow 
cytometric analysis of cell viability in the indicated cell lines after inducing expression of shJAK1#5 or 
a control shRNA for the indicated times. The viability of shJAK1#5-expressing/ GFP+ cells was 
normalized to that of the cells transduced with control shRNA for each time point and then normalized 
to day 0 values. Data are representative of three independent experiments. 
 
Fig. 2. Constitutively activated STAT3 (STAT3-C) does not rescue viability ABC DLBCL cells 
following JAK1 knockdown. (A) Immunoblot analysis of the indicated proteins in TMD8 and HBL1 
ABC DLBCL cells transduced with STAT3-C or empty vector, after 2 days of doxycycline induction 
of STAT3-C expression. (B)  Flow cytometric analysis of TMD8 and HBL1 ABC DLBCL cells 
transduced with STAT3-C or empty vector following induction of shSTAT3.  Shown are the 
percentages of shSTAT3+/GFP+ cells over time of shSTAT3 induction.  (C) Flow cytometric analysis 
of TMD8 and HBL1 ABC DLBCL cells transduced with STAT3-C, JAK1 or empty vector following 
induction of shJAK1.  Shown are the percentages of shJAK1+/GFP+ cells over time of shJAK1 
induction. Data are representative of three independent experiments. 
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Fig. 3. Nuclear JAK1 phosphorylates H3Y41 and upregulates MYC expression in ABC DLBCL. 
(A) Immunoblot analysis of the indicated proteins in cytoplasmic (C) and nuclear (N) fractions of 
TMD8 and HBL1 ABC DLBCL cells. (B) Immunoblot analysis of the indicated proteins in TMD8 
cells after 2 days of shRNA doxycycline-induced expression of shJAK1#5, shJAK2 or a control 
shRNA. (C) Immunoblot analysis of the indicated proteins in TMD8 cells after treatment with the JAK 
inhibitors AZD1480 (2 μM) or ruxolitinib (4 μM) for the indicated times. (D) ChIP analysis of 
H3Y41-P at the MYC locus in TMD8 cells with and without treatment with AZD1480 (2 μM) for 4 
hours.  Quantitative PCR was performed using the primers targeting the indicated regions of the MYC 
locus and negative control primers targeting the ubiquitin B promoter.  The mean values of H3Y41-P 
signals were normalized to the input DNA signal.  ChIP using IgG is shown as a negative control.  
Error bars represent SD (n=3).  
 
Fig. 4. H3Y41-P ChIP-Seq in the ABC DLBCL TMD8 cell line.  (A) Distribution of H3Y41-P 
peaks relative to protein-coding genes in the TMD8 ABC DLBCL cell line. TMD8 cells were treated 
with AZD1480 (2 μM) or DMSO for 4 hours before ChIP-Seq (see text for details). (B) Frequency 
histogram of H3Y41-P ChIP-Seq tags mapping in the proximity of an annotated transcriptional start 
site (TSS) of a protein-coding gene in TMD8 cells. (C) Density heat-maps of H3Y41-P ChIP-Seq 
sequence tags displayed relative to ChIP-Seq peak apex.  Peak calling was performed in DMSO-
treated TMD8 cells and peaks were assigned to locations relative to protein-coding genes as in (A). 
Genes were ranked by H3Y41-P density in DMSO-treated cells (-500bp to +500bp from peak apex) 
and the heat maps for each gene in cells treated with the JAK inhibitor AZD1480 (2 μM) are displayed 
accordingly. (D) Fischer’s exact test of the overlap between the set of genes with H3Y41-P peaks and 
the sets of genes that were either downregulated or upregulated by AZD1480 treatment (2 μM) of 
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TMD8 cells. The -log10 enrichment p-value is shown. (E) Gene Set Enrichment Analysis (GSEA) 
comparing H3Y41-P-containing genes and genes downregulated by AZD1480 in TMD8 cells. Genes 
were ranked based on the changes induced by AZD1480 treatment, and H3Y41-P genes were 
displayed accordingly (black lines). The corresponding Kolmogorov-Smirnov (KS) score is shown in 
green (P-value=2.92 E-07, see methods for detail).  (F) Overlap between the sets of genes 
downregulated or upregulated by AZD1480 treatment of TMD8 cells and gene expression signatures 
described in reference (29). Shown is the enrichment ratio relative to the overlap expected by chance.  
(G)  The H3Y41-P ChIP-Seq tracks of DMSO-treated (red) or AZD1480-treated (black) TMD8 cells 
are shown for the indicated genes. The coverage depth is displayed and depths greater than 25 are 
truncated.  (H) TMD8 or OCI-Ly10 ABC DLBCL cells were treated with 2 μM AZD1480 before 
immunoblot analysis of the indicated proteins.  Below shows quantitative PCR analysis of MYD88 and 
IRF4 mRNA levels (normalized to beta-2-microglobulin mRNA levels). Error bars represent mean ± 
SD of triplicates. 
 
Fig. 5. Synergy of JAK1 inhibition and ibrutinib in killing of ABC DLBCL cells. (A) The 
indicated DLBCL lines were treated with the indicated concentrations of AZD1480 and/or ibrutinib for 
6 days and evaluated for viability by trypan blue dye exclusion.  Both drugs were replenished on day 3.  
Error bars represent mean ± SD of triplicates. The GCB DLBCL cell line OCI-Ly19 served as a 
negative control cell line.  Data are normalized to toxicity of treatment with the indicated 
concentrations of ibrutinib alone.  A shift of the AZD1480 toxicity curves to the left indicates a greater 
than additive effect of the two drugs.   (B) Ibrutinib increases JAK1 shRNA toxicity in TMD8 and 
OCI-Ly10 cells. Flow cytometric analysis of the percentage of viable, shJAK1-expressing cells in the 
presence of 5 nM ibrutinib or DMSO.  (C) Immunoblot analysis of the indicated proteins in OCI-Ly10 
ABC DLBCL cells after 48 hours of treatment with the indicated concentrations of AZD1480 +/– 1 
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nM ibrutinib.  Shown below are IRF4 and MYD88 protein levels relative to β-actin levels as quantified 
by densitometry. 
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